Skip to search formSkip to main contentSkip to account menu

ANTI-INHIBITOR COAGULANT COMPLEX

Known as: coagulation factor IX, II, VII and X in combination, Factor VIII bypassing fraction, Factor VIII inhibitor bypassing activity 
A sterile, freeze dried fraction of human plasma containing factor VIII coagulant antigen and both the inactive and active forms of coagulation… 
National Institutes of Health

Related topics

Related topics

10 relations
ANTI-INHIBITOR COAGULANT COMPLEX 1 UNT InjectionDrug AllergyEnzyme Activators [MoA]Reversed Anticoagulation Activity [PE]

Narrower (2)

ANTI-INHIBITOR COAGULANT COMPLEX 1 UNT Injection [Feiba]Feiba

Broader (2)

Blood Coagulation FactorCoagulants

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2011
Highly Cited
2011
Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents.
Edoxaban, an oral, direct factor Xa inhibitor, has a similar or low incidence of bleeding events compared with other… 
Review
2011
Review
2011
Why caretakers bypass Primary Health Care facilities for child care - a case from rural Tanzania
BackgroundResearch on health care utilization in low income countries suggests that patients frequently bypass PHC facilities in… 
Highly Cited
2007
Highly Cited
2007
A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study.
The development of inhibitory antibodies to factor VIII is a serious complication of hemophilia. FEIBA (factor VIII inhibitor… 
Highly Cited
2005
Highly Cited
2005
Major surgery in a severe haemophilia A patient with high titre inhibitor: use of the thrombin generation test in the therapeutic decision
Summary.  In haemophilia patients with inhibitor, elective orthopaedic surgery is usually performed under recombinant activated… 
Review
2004
Review
2004
Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors
Summary.  Recombinant factor (rF)VIIa has been available to clinicians since 1996 and has an excellent safety record after almost… 
Highly Cited
2004
Highly Cited
2004
Treatment of acquired haemophilia with factor eight inhibitor bypassing activity
Summary.  Haemorrhagic manifestations in patients with acquired haemophilia can be fatal if not recognized and treated… 
Highly Cited
2004
Highly Cited
2004
Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity
  • L. Aledort
  • Journal of Thrombosis and Haemostasis
  • 2004
  • Corpus ID: 34862036
Summary.  Thrombosis is a rare but well‐recognized potential complication of Factor VIII Inhibitor Bypass Activity (FEIBA… 
Highly Cited
2003
Highly Cited
2003
Factor VIII Inhibitor-Bypassing Agents Act by Inducing Thrombin Generation and Can Be Monitored by a Thrombin Generation Assay
Factor VIII (FVIII)-bypassing agents have complex modes of action but all control bleeding in inhibitor patients by triggering… 
Highly Cited
2001
Highly Cited
2001
Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor.
Highly Cited
1997
Highly Cited
1997
Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity.
Factor VIII or factor IX replacement is frequently impossible in inhibitor-developing hemophiliacs, because of the level of the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)